Peruna

oral · 1879–1918

category:oral

delivery:A bottled liquid tonic taken by the spoonful or wineglassful, sold nationally through druggists for one dollar a bottle, and promoted through newspaper and almanac advertising, unsolicited-testimonial booklets, and endorsements solicited from clergy and members of Congress.

price tier:not classified

era:1879–1918

current status:historical

regulatory:withdrawn

SHORT PITCH (AS SOLD)

A dollar bottle that redefined nearly every disease as a form of 'catarrh' -- pneumonia, appendicitis, Bright's disease, even yellow fever -- and promised Pe-ru-na never fails to cure catarrh wherever located, discovered and endorsed personally by its inventor, Dr. S. B. Hartman.

THE ACTUAL EVIDENCE

Samuel Hopkins Adams's 1905 Collier's Weekly investigation, later reprinted by the American Medical Association in The Great American Fraud (1907), found Peruna to be essentially cologne spirits, water, and a trace of flavoring and mild drugs, and called it flatly 'a stimulant pure and simple' (Adams 1907). Product labels of the period stated the alcohol content directly -- 'Alcohol 28%' (Lockhart et al. 2025, quoting Fike 1987) -- and in 1905 the federal government banned Peruna's sale on Indian reservations for that same reason (Lockhart et al. 2025). Hartman himself, in the interview Adams published, undercut the product's entire premise: he 'stated to me specifically and repeatedly that no drug or combination of drugs, with the possible exception of quinin for malaria, will cure disease' (Adams 1907). Adams called the broader catalogue of catarrh-cure claims -- covering pneumonia, dyspepsia, appendicitis, Bright's disease, heart disease, and, promoted during a New Orleans epidemic, prevention of yellow fever -- 'too ridiculous to need refutation' given the product's actual contents (Adams 1907). An Internal Revenue liquor-tax ruling forced Hartman to cut the alcohol content to roughly 18 percent and add laxatives so the product could still be sold as medicine rather than taxed as liquor; the 1906 Pure Food and Drug Act separately required alcohol disclosure on the label (Adams 1907). Sales collapsed so badly that Hartman tried reviving the original high-alcohol formula under a different name, Katarno, which never caught on (Sullivan 2007; Lockhart et al. 2025). Writing in 1922, the American Medical Association's own habit-cure pamphlet noted dryly that Peruna, once 'sold by car-load lots,' was 'now...sold by the case' (Lockhart et al. 2025, quoting the Journal of the American Medical Association, 1922). No source in this bundle documents any clinical trial, contemporaneous or later, supporting a catarrh-cure, disease-prevention, or yellow-fever-preventive effect for Peruna. A later owner still advertised Peruna in 1983 (Lockhart et al. 2025). A dated 2026 search found no current manufacturer, retailer, or trademark holder using the Peruna name. The reachable peruna.com address led only to a GoDaddy/Afternic domain-for-sale page with no established connection to the historical product.

PRACTITIONERS

Dr. Samuel B. Hartman

INGREDIENTS

Peruna tonic base (cologne spirits, water, and undisclosed 'mild drugs')

CASES

hartman-peruna-1889-1913

CLAIMS

Half our ills are catarrhal in nature... Pe-ru-na never fails to cure catarrh wherever located -- of the head, nose, throat, lungs, stomach, and pelvic organs, and chronic, winter, and summer catarrh. refuted
Peruna, though not a cure-all, is advertised as a preventative against yellow fever. refuted
Peruna is not an alcoholic beverage but a legitimate medicine -- Dr. Hartman called the charge that he trafficked in liquor a shock 'beyond all measure,' and recommended Peruna even for children. refuted

SOURCES

NOTES

Peruna was a proprietary bottled tonic developed by Dr. Samuel B. Hartman, first advertised in 1879 and sold nationally by the 1890s as a cure for “catarrh” — a diagnosis Hartman’s own promotional literature stretched to cover most of the era’s serious and minor diseases (Lockhart et al. 2025; Adams 1907). It is a patent-medicine case in the mold of the era’s other proprietary panaceas: a single bottled formula, marketed under one physician’s name and personal authority, distributed broadly through ordinary druggists, and reaching, by 1905, an estimated $1 million a year in advertising spending alone (Sullivan 2007).

The price_tier is recorded as unknown: bottles sold for one dollar each nationwide — a comparison in one secondary account notes twenty-five cents then bought a full lunch (Sullivan 2007) — but no attached source characterizes that price’s affordability or market placement for a displayed period as opposed to simply narrating the number, so a concrete tier is not asserted. The longevity and health dimension is squarely the promise of curing named, serious disease (pneumonia, Bright’s disease, appendicitis, heart disease) and preventing others (yellow fever) as well as ordinary discomfort, positioning the product as a route to sustained health rather than merely symptom relief. None of it withstood contemporaneous scrutiny: the product’s own promoter admitted to a reporter that almost no drug cures disease, chemical and label evidence put its actual content at roughly 28 percent grain alcohol before 1906, and the federal government had already banned its sale on Indian reservations for exactly that reason. The withdrawn regulatory status records that the original claims and formulation did not survive federal scrutiny. An Internal Revenue liquor-tax ruling forced the addition of laxatives and a reduction in alcohol; Peruna never regained its former top-selling status, though a later owner still advertised it in 1983 (Adams 1907; Sullivan 2007; Lockhart et al. 2025). A dated 2026 search found no current product or successor company.